19:53 , Jan 13, 2017 |  BC Week In Review  |  Clinical News

VT-1161: Additional Ph IIb REVIVE data

Additional data from the double-blind, U.S. Phase IIb REVIVE trial in 215 patients with recurrent vulvovaginal candidiasis showed that 150 and 300 mg doses of oral VT-1161 once daily for 7 days and then once...
19:53 , Jan 13, 2017 |  BC Week In Review  |  Clinical News

VT-1161: Additional Ph IIb RENOVATE data

Additional data from the double-blind, U.S. Phase IIb RENOVATE trial in 259 patients with distal lateral subungual onychomycosis of the large toenail showed that 300 and 600 mg doses of oral VT-1161 once daily for...
07:00 , Oct 17, 2016 |  BC Week In Review  |  Clinical News

VT-1161 regulatory update

FDA granted Qualified Infectious Disease Product (QIDP) designation to VT-1161 from Viamet to treat recurrent vulvovaginal candidiasis. VT-1161 is in a Phase IIb trial for the indication (see BioCentury, March 14). The product is an...
07:00 , Sep 19, 2016 |  BC Week In Review  |  Clinical News

VT-1598 regulatory update

FDA granted Qualified Infectious Disease Product (QIDP) designation to VT-1598 from Viamet to treat coccidioidomycosis (valley fever). VT-1598 is in preclinical testing. The compound is an oral inhibitor of fungal cytochrome P450 C-14 alpha...
07:00 , Aug 22, 2016 |  BioCentury  |  Emerging Company Profile

Metal smithing

Forge Therapeutics Inc. is using a library of metal-binding pharmacophores that avoid known pharmacologic and safety liabilities of a common metal-binding motif to create inhibitors of metalloenzymes, starting with notoriously tough targets. Forge's lead program...
07:00 , Mar 14, 2016 |  BC Week In Review  |  Clinical News

VT-1161: Interim Phase IIb data

Interim data from about 100 patients with distal lateral subungual onychomycosis of the large toenail in the double-blind, U.S. Phase IIb RENOVATE trial showed that 300 and 600 mg oral VT-1161 once daily for 2...
07:00 , Mar 14, 2016 |  BC Week In Review  |  Clinical News

VT-1161: Interim Phase IIb data

Interim data from about 100 patients with recurrent vulvovaginal candidiasis in the double-blind, U.S. Phase IIb REVIVE trial showed that 150 and 300 mg oral VT-1161 once daily for 7 days and then once-weekly for...
07:00 , Sep 28, 2015 |  BC Week In Review  |  Company News

Viamet, Mycoses Study Group Education and Research Consortium deal

Viamet and the Mycoses Study Group Education & Research Consortium (MSGERC) partnered to discover and develop therapies to treat cryptococcal meningitis and other fungal infections. The deal will focus on Viamet’s VT-1129, an oral...
07:00 , Sep 21, 2015 |  BC Week In Review  |  Clinical News

VT-1129 regulatory update

FDA granted Qualified Infectious Disease Product (QIDP) designation to VT-1129 from Viamet to treat cryptococcal meningitis. Viamet plans to start Phase I testing of the product next quarter. VT-1129 is an oral small molecule inhibitor...
07:00 , Mar 23, 2015 |  BC Week In Review  |  Clinical News

VT-1161: Phase IIb started

Viamet began the double-blind, placebo-controlled, U.S. Phase IIb RENOVATE trial to evaluate 300 and 600 mg oral VT-1161 once daily for 2 weeks followed by once weekly for 10 or 22 weeks in about 250...